Cost-effectiveness analysis of different protease inhibitors-based strategies in the treatment of naive patients with genotype 1 chronic hepatitis C (G1-CHC)

Trial Profile

Cost-effectiveness analysis of different protease inhibitors-based strategies in the treatment of naive patients with genotype 1 chronic hepatitis C (G1-CHC)

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 May 2015

At a glance

  • Drugs Boceprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms ADVANCE; SPRINT-2
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 29 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top